Keyword: niraparib

FDAApprovedStamp

The top 10 drug launches of 2017

Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.

5. Niraparib

Niraparib wouldn't be the first PARP-inhibiting drug on the market, but Tesaro is hoping that its entry will launch with a bigger target, thanks to study data showing it delivered benefits not only to women with the BRCA gene mutation, but those without.
FDAApprovedStamp

The top 10 drug launches of 2017

After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017. One thing’s for sure, though: No matter what total the industry tallies up this year, the crop will bring some would-be blockbusters and market disrupters.